US Domestic shipping is available for this product! Choose Ships from: US size option to get it in 3-7 days to any US address. Dont forget to choose US Domestic Shipping when checking out
It is now hard to believe, but Cerebrolysin ® -- perhaps the most efficient peptide nootropic -- was developed when the scientific community had a very limited understanding of how the central nervous system works.
The drug was created in 1949 by Gerhart Harrer, an Austrian Professor, and approved on 1 August 1954. After many success stories, extensive research and discovery of neurotrophic regulation, its popularity has increased drastically and now it can officially be used as a treatment for various cerebral disorders in 44 countries, mostly in Europe and Asia.
Cerebrolysin ® is a neurometabolic stimulator based on neuropeptides (20%) and amino acids (80%) isolated from pig brain tissue.
Unlike the majority of peptide drugs, Cerebrolysin has all the amino acids which compose the central nervous system; this can explain many additional positive properties of Cerebrolysin.
Cerebrolysin has been proven to be efficient when used for:
- Strokes and stroke complications
- Alzheimer’s disease and other types of dementia
- Traumatic brain injuries
- Spinal cord injuries
- ADHD in children
- Antidepressant-resistant depressions
- Other cerebral diseases
Like Semax, Cerebrolysin is on the Russian List of Vital & Essential Drugs.
Country of Manufacture: Austria
Here you can read more TopBrainBoosters review of Cerebrolysin
Here is the original 84-pages Cerebrolysin Monograph from EverNeuro Pharma, where you can find a lot of information
And here is the Certificate Of Analysis, where you can find the information on one of the batches that we sold. It was asked by one of our clients and we went an extra mile.
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease.